The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Nurse practitioners and physician assistants can advocate to play a number of roles in oncology research, including primary ...

Both those receiving either expected or less-than-expected starting dosages of ruxolitinib for myelofibrosis treatment ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

According to a nurse practitioner who works in myeloma research, nurses and APPs are responsible for much of the clinical ...

Despite the COVID-19 pandemic and related health care disruptions that caused a decrease in cancer incidence, overall cancer ...

AYA Cancer Awareness month offers an opportunity for nurses to go further in supporting AYAs with cancer.

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...

Panelists discuss how cardiovascular toxicity remains a significant concern with certain tyrosine kinase inhibitors (TKIs) ...

Panelists discuss how eliminating the strict mealtime restrictions with the new nilotinib formulation addresses a significant ...